|Stemline Therapeutics, Inc.|
750 Lexington Avenue
United States - Map
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. It develops SL-401, a clinically active targeted therapy directed to the interleukin-3 receptor, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, a clinically active therapeutic cancer vaccine that has completed two Phase I/II clinical trials. The company was founded in 2003 and is headquartered in New York, New York.
|Stemline Therapeutics, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Ivan Bergstein M.D.,
Founder, Chairman, Chief Exec. Officer and Pres
|Mr. David G. Gionco ,
Chief Accounting Officer and VP of Fin.
|Mr. Kenneth Hoberman ,
Chief Operating Officer and Corp. Sec.
|Dr. Eric K. Rowinsky M.D.,
Chief Medical Officer, Head of R&D and Exec. VP
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|